Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Cipla's generic version of Abraxane receives final FDA approval, launching in the U.S. by September for cancer treatment.

Lung cancer is the number one cancer killer in the world. Biomarker testing improves outcomes in stage IV non-small cell lung cancer (NSCLC), however its ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.

Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable ...

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Therapies that unleash the immune system to fight tumors have greatly extended the lives of people with many types of cancer.

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC ...